Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-06-12T13:57:18.026Z Has data issue: false hasContentIssue false

Old drugs vs. new drugs: Treating bipolar disorder in children and adolescents

Published online by Cambridge University Press:  16 April 2020

P.T. Dineen
Affiliation:
Oxford City Child & Adolescent Mental Health Service, Oxford Psychopharmacology Unit, University of Bristol, Bristol, UK
A.L. Malizia
Affiliation:
Psychopharmacology Unit, University of Bristol, Bristol, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This is a literature review of the evidence for pharmacological treatment for bipolar disorder in children and adolescents. The review covers drugs that have controlled studies and is divided into older, classical antimanic drugs and the newer mood-stabliser/antipsychotic drugs. The drugs that have had controlled studies are aripiprazole, lithium, olanzapine, oxcarbazepine, quetiapine, risperidone, topiramate, valproate/divalproex drugs and ziprasidone. Carbamazepine, lamotrigine and nefazodone (which is included for completion) were not found to have any evidence from controlled studies. Of the 9 drugs that have evidence, it was found that the newer second-generation antipsychotics had better evidence for efficacy for management of acute mania in children and adolescents: aripiprazole, risperidone, quetiapine and olanzapine. Classical antimanic agents such as lithium and valproate-based drugs had limited evidence.

Type
P01-276
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.